Description
David Goeddel is a molecular biologist who was involved in engineering synthetic insulin, human tissue plasminogen activator (tPA), and human growth hormone. He worked for the company Genentech and later co-founded the pharmaceutical company Tularik, of which he became the CEO. In this interview, Goeddel discusses his undergraduate and graduate research, working at the Stanford Research Institute, the projects and people at Genentech, establishing and working at Tularik, the human insulin and human growth hormone projects, and the University of California and Genentech lawsuit.